1. Apartsin KA, Zaritskaya LV, Grigor’ev SE, Lepekhova SA. The possibility of using Selank for medical correction postsplenectomy immunodeficiency. Allergol. Immunol. 2006;7(3):429. Russian.
2. Vasilieva LS, Molokov VD, Ivanova NI, Ivanov KB. Effects of local application of anxiolitiс in the medication of experimental parodontitis. Sib. Med. Zh. (Irkutsk). 2014;126(3):55-58. Russian.
3. Kozlovskaya MM, Neznamov GG, Koshelev VV, Teleshova ES, Bochkareva VK. Results of clinical and pharmacological studies of Selank peptide preparation as the anxiolytic agent. Sots. Klin. Psikhiatiya. 2003;13(4):28-36. Russian.
4. Kolomin TA, Agapova TYu, Agniullin YaV, Shram SI, Shadrina MI, Slominskii PA, Limborskaya SA, Myasoedov NF. Changes in the transcriptional profile of the hippocampus in response to the introduction of taftsin analog selank. Zh. Vyssh. Nervn. Deyat. 2013;63(3):365. Russian.
5. Kolomin TA, Shadrina MI, Agniullin YV, Shram SI, Slominskii PA, Limborska SA, Myasoedov NF. Transcriptomic response of rat hippocampus and spleen cells to single and chronic administration of the peptide selank. Dokl. Biochem. Biophysics. 2010;430(1):5-6.